secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001809519-24-000133
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx adds former Genentech CEO Ian Clark to board, creates Innovation Committee
--------------------------------------------------------------------------------

- Ian T. Clark elected Class III director effective July 8, 2024; fills vacancy from Stephen LeSieur's March resignation.
- Clark chairs newly created Innovation Committee; also joins Nominating and Corporate Governance Committee.
- Granted initial RSU award worth $420,000 and pro-rated annual award of $209,836 under director compensation plan.
- Board combined Audit and Compliance committees into a single Audit and Risk Committee.
- Clark brings 35+ years pharma/healthcare experience; board deems him independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000133/0001809519-24-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000133/gdrx-20240708.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer